Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Pro Medicus Limited ( (AU:PME) ).
Pro Medicus Limited announced that its U.S. subsidiary, Visage Imaging, Inc., has received an Authority to Operate (ATO) from the U.S. Department of Veterans’ Affairs for its Visage 7 | CloudPACS platform. This milestone allows the transition of their current on-premise system to the Veterans Affairs Enterprise Cloud, marking a significant step in their collaboration with the Veterans’ Health Administration. The achievement is expected to serve as a reference for other Veterans’ Integrated Service Networks considering cloud migration, potentially enhancing Pro Medicus’s positioning in the federal healthcare sector.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$338.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading healthcare informatics company founded in 1983. It provides a comprehensive range of medical imaging software and services to hospitals, imaging centers, and healthcare groups globally. The company’s Visage 7 suite offers advanced, scalable imaging solutions deployable in both public and private cloud environments. Pro Medicus operates offices in Melbourne, Berlin, and San Diego.
YTD Price Performance: 19.58%
Average Trading Volume: 174,000
Technical Sentiment Signal: Buy
Current Market Cap: A$31.23B
For a thorough assessment of PME stock, go to TipRanks’ Stock Analysis page.